Prelude Therapeutics Incorporated PRLD · Stock Open Prelude Therapeutics Incorporated in new tab
Prelude Therapeutics Incorporated Analysis (PRLD)
Is Prelude Therapeutics Incorporated a good investment? Prelude Therapeutics Incorporated (PRLD) is currently trading at 4.70 USD. Market analysts have a consensus price target of 9.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: Prelude Therapeutics Incorporated is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.77.
Investor FAQ
Does Prelude Therapeutics Incorporated pay a dividend?
No, it does not currently pay a dividend.
What asset class is Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.73.
Company Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Community Discussion